Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.55 |
| ▸ | PPARD | Q03181 | 4/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3892378 | 1.00 | PPARA (0.68) | PPARACHRM4PPARDPPARGGAA | |
| SCHEMBL3888972 | 1.00 | PPARA (0.68) | PPARACHRM4PPARDPPARGGAA | |
| SCHEMBL5487834 | 0.94 | PPARA (0.60) | PPARACHRM4PPARDPPARGGAA | |
| SCHEMBL3892372 | 0.92 | PPARA (0.65) | PPARACHRM4PPARDPPARGGAA | |
| SCHEMBL2069036 | 0.89 | PPARA (0.73) | PPARACHRM4PPARDPPARGGAA | |
| SCHEMBL2070819 | 0.89 | PPARA (0.73) | PPARACHRM4PPARDPPARGGAA | |
| SCHEMBL2069034 | 0.89 | PPARA (0.73) | PPARACHRM4PPARDPPARGGAA | |
| SCHEMBL3890236 | 0.88 | PPARA (0.63) | PPARACHRM4PPARDPPARGGAA | |
| SCHEMBL3905841 | 0.87 | PPARA (0.57) | PPARACHRM4PPARDPPARGGAA | |
| SCHEMBL3889709 | 0.87 | PPARA (0.68) | PPARACHRM4PPARDPPARGGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | claimed |
| EP-1862464-A1 | NOVEL CYCLIC AMINOPHENYLALKANOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-12-05 | — | — | EP | claimed |
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | PPARA, PPARD, PPARG | PPARA 1/4885CHRM4 2809/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.